Last reviewed · How we verify

ABT-450/r/ABT-267, ABT-333

AbbVie (prior sponsor, Abbott) · Phase 3 active Small molecule

ABT-450/r/ABT-267, ABT-333 is a HCV protease inhibitor and non-nucleoside polymerase inhibitor combination Small molecule drug developed by AbbVie (prior sponsor, Abbott). It is currently in Phase 3 development for Chronic hepatitis C virus (HCV) infection, genotype 1. Also known as: Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir.

This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.

This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes. Used for Chronic hepatitis C virus (HCV) infection, genotype 1.

At a glance

Generic nameABT-450/r/ABT-267, ABT-333
Also known asViekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK
SponsorAbbVie (prior sponsor, Abbott)
Drug classHCV protease inhibitor and non-nucleoside polymerase inhibitor combination
TargetHCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhasePhase 3

Mechanism of action

ABT-450/r (ritonavir-boosted protease inhibitor) and ABT-333 (non-nucleoside NS5B polymerase inhibitor) work synergistically to suppress HCV replication. ABT-450/r inhibits the HCV NS3/4A serine protease, which is essential for viral polyprotein processing, while ABT-333 directly inhibits the NS5B RNA-dependent RNA polymerase. The ritonavir component boosts ABT-450 plasma concentrations through CYP3A4 inhibition.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ABT-450/r/ABT-267, ABT-333

What is ABT-450/r/ABT-267, ABT-333?

ABT-450/r/ABT-267, ABT-333 is a HCV protease inhibitor and non-nucleoside polymerase inhibitor combination drug developed by AbbVie (prior sponsor, Abbott), indicated for Chronic hepatitis C virus (HCV) infection, genotype 1.

How does ABT-450/r/ABT-267, ABT-333 work?

This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.

What is ABT-450/r/ABT-267, ABT-333 used for?

ABT-450/r/ABT-267, ABT-333 is indicated for Chronic hepatitis C virus (HCV) infection, genotype 1.

Who makes ABT-450/r/ABT-267, ABT-333?

ABT-450/r/ABT-267, ABT-333 is developed by AbbVie (prior sponsor, Abbott) (see full AbbVie (prior sponsor, Abbott) pipeline at /company/abbvie-prior-sponsor-abbott).

Is ABT-450/r/ABT-267, ABT-333 also known as anything else?

ABT-450/r/ABT-267, ABT-333 is also known as Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK.

What drug class is ABT-450/r/ABT-267, ABT-333 in?

ABT-450/r/ABT-267, ABT-333 belongs to the HCV protease inhibitor and non-nucleoside polymerase inhibitor combination class. See all HCV protease inhibitor and non-nucleoside polymerase inhibitor combination drugs at /class/hcv-protease-inhibitor-and-non-nucleoside-polymerase-inhibitor-combination.

What development phase is ABT-450/r/ABT-267, ABT-333 in?

ABT-450/r/ABT-267, ABT-333 is in Phase 3.

What are the side effects of ABT-450/r/ABT-267, ABT-333?

Common side effects of ABT-450/r/ABT-267, ABT-333 include Nausea, Fatigue, Headache, Diarrhea.

What does ABT-450/r/ABT-267, ABT-333 target?

ABT-450/r/ABT-267, ABT-333 targets HCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase and is a HCV protease inhibitor and non-nucleoside polymerase inhibitor combination.

Related